Page 233 - 2021_07-Haematologica-web

Letters to the Editor
the safety profile of ACT017 still holds true when com- bining it with other drugs like recombinant tissue-type plasminogen activator remains to ascertain, but the absence of effect of ACT017 on platelet recruitment to the inflamed vasculature suggests there is a realistic chance for it to be maintained.
Soumaya Jadoui,1* Ophélie Le Chapelain,1*
Véronique Ollivier,1 Ali Mostefa-Kara,1 Lucas Di Meglio,1 Sébastien Dupont,1 Angèle Gros,1 Mialitiana Solo
1 1,2 1,2 Nomenjanahary, Jean-Philippe Desilles, Mikaël Mazighi,
Bernhard Nieswandt,3 Stéphane Loyau,1 Martine Jandrot-Perrus,1 Pierre H. Mangin4 and Benoit Ho-Tin-Noé1
1Université de Paris, LVTS, INSERM U1148, Paris, France; 2Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France; 3University Hospital Würzburg, Rudolf Virchow Center for Experimental Biomedicine, Würzburg, Germany and 4Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France
*SJ and OLC contributed equally as co-first authors. Correspondence:
BENOIT HO-TIN-NOE’ - benoit.ho-tin-noe@inserm.fr doi:10.3324/haematol.2020.270439
Received: August 25, 2020.
Accepted: December 21, 2020.
Pre-published: December 30, 2020.
Disclosures: MJ-P is the founder of Acticor Biotech; all other authors have no conflicts of interest to disclose.
Contributions: SJ, OLC, VO, MSN, AM,LDM, SD, AG, and SL performed research and data analysis; JPD, MM, MJP, BN, and PHM provided critical feedback and helped shape the research; BTHN supervised the study, performed research and data analysis, and wrote the manuscript with support of SJ, OLC, VO, SD and MJP; all authors discussed the results and contributed to the final manuscript.
Funding: this work was supported by grants from INCA (2016-09/435/NI-KA), La Fondation ARC (PJA 20151203107), La Fondation pour la Recherche Médicale (grant #DPC20171138959), and by public grants overseen by the French National Research Agency (ANR) as part of the Investments for the Future program (PIA) under grant agreement No. ANR-18-RHUS-0001 (RHU Booster) and BPI (CMI2 project TherAVC2.0); SJ was awarded
a grant from la Société Française d’Hématologie.
References
1. Mangin PH, Tang CJ, Bourdon C, et al. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharmacol Exp Ther. 2012;341(1):156-163.
2.Dütting S, Bender M, Nieswandt B. Platelet GPVI: a target for
antithrombotic therapy?! Trends Pharmacol Sci. 2012;33(11):583-
590.
3. Jiang P, Jandrot-Perrus M. New advances in treating thrombotic dis-
eases: GPVI as a platelet drug target. Drug Discov Today. 2014;
19(9):1471-1475.
4. Stegner D, Haining EJ, Nieswandt B. Targeting glycoprotein vi and
the immunoreceptor tyrosine-based activation motif signaling path-
way. Arterioscler Thromb Vasc Biol. 2014;34(8):1615-1620.
5. Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019;
129(1):12-23.
6. Rayes J, Jadoui S, Lax S, et al. The contribution of platelet glycopro-
tein receptors to inflammatory bleeding prevention is stimulus and
organ dependent. Haematologica. 2018;103(6):e256-e258.
7. Gros A, Syvannarath V, Lamrani L, et al. Single platelets seal neu- trophil-induced vascular breaches via GPVI during immune-com- plex-mediated inflammation in mice. Blood. 2015;126(8):1017-1026. 8. Hillgruber C, Pöppelmann B, Weishaupt C, et al. Blocking neu- trophil diapedesis prevents hemorrhage during thrombocytopenia. J
Exp Med. 2015;212(8):1255-1266.
9. Boulaftali Y, Hess PR, Getz TM, et al. Platelet ITAM signaling is crit-
ical for vascular integrity in infammation. J Clin Invest. 2013;
123(2):908-916.
10. Maestrini I, Strbian D, Gautier S, et al. Higher neutrophil counts
before thrombolysis for cerebral ischemia predict worse outcomes.
Neurology. 2015;85(16):1408-1416.
11. Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noé B. Pathology
of human plaque vulnerability: mechanisms and consequences of
intraplaque haemorrhages. Atherosclerosis. 2014;234(2):311-319. 12. Voors-Pette C, Lebozec K, Dogterom P, et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab: first-in-human healthy vol-
unteer trial. Arterioscler Thromb Vasc Biol. 2019;39(5):956-964.
13. Lecut C, Feeney LA, Kingsbury G, et al. Human platelet glycopro- tein VI function is antagonized by monoclonal antibody-derived fab
fragments. J Thromb Haemost. 2003;1(12):2653-2662.
14. Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P. Design, development and characterization of ACT017, a human- ized Fab that blocks platelet’s glycoprotein VI function without
causing bleeding risks. MAbs. 2017;9(6):945-958.
15.Ho-Tin-Noé B, Boulaftali Y, Camerer E. Platelets and vascular
integrity: how platelets prevent bleeding in inflammation. Blood.
2018;131(3):277-288.
16. Kraft P, Schuhmann MK, Fluri F, et al. Efficacy and safety of platelet
glycoprotein receptor blockade in aged and comorbid mice with
acute experimental stroke. Stroke. 2015;46(12):3502-3506.
17. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115(17):2323-
2330.
18. Claushuis TAM, de Vos AF, Nieswandt B, et al. Platelet glycoprotein
VI aids in local immunity during pneumonia-derived sepsis caused
by gram-negative bacteria. Blood. 2018;131(8):864-876.
19. Volz J, Mammadova-Bach E, Gil-Pulido J, et al. Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of
chemotherapy in mice. Blood. 2019;133(25):2696-2706.
20. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not a2β1 integrin is essential for platelet interaction with colla-
gen. EMBO J. 2001;20(9):2120-2130.
haematologica | 2021; 106(7)
2003